Pharmaceutical product permissions

A searchable record of what Walter is equipped to evaluate.

Explore compositions across oral solids, oral liquids, sterile injectables, topical formats and selected specialist presentations. Use the catalogue to begin a technical and commercial discussion—not as a substitute for written facility-specific confirmation.

5,500Distinct records
21Dosage forms
407Sterile injectable records
17Therapeutic indexes

Built for portfolio teams

Move from a molecule search to a focused feasibility conversation.

The catalogue brings together composition, strength, pharmacological class, dosage form, manufacturing stream, BCS class and documented regulatory references. It also incorporates products listed in Walter’s March 2025 Injectables Manufacturing Profile. Therapeutic and pharmacological classes are practical navigation labels; final indication, regulatory position and site suitability are confirmed product by product.

Search the catalogue

Selected catalogue briefs

Explore a composition for your manufacturing brief.

Browse selected compositions by dosage form, then share the required strength, pack, quantities and target market for a product-specific feasibility review.

Search the full catalogue
Browse 26 selected composition briefs

Therapeutic index

Begin with the treatment area.

Each composition is assigned to one practical primary area for navigation. Combination products may span more than one clinical use and remain subject to product-specific review.

Searchable permissions catalogue

Find a composition, dosage form or capability route.

5,500distinct permission records

Loading full catalogue search…
Therapeutic area
Dosage-form family
Specific dosage form
Pharmacological class
Manufacturing stream
BCS classification
Confirmed CDSCO category
Drugs Rules status

24 records shown

CardiovascularPRM 4622
Dosage formHard-gelatin capsules
Oral

Acebutolol Hcl 100 mg

Route
Oral
Formulation type
Hard-capsule oral solid
Pharmacological class
Beta blocker
Manufacturing stream
Non-beta-lactam
BCS class
Class III
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 4623
Dosage formHard-gelatin capsules
Oral

Acebutolol Hcl 200 mg

Route
Oral
Formulation type
Hard-capsule oral solid
Pharmacological class
Beta blocker
Manufacturing stream
Non-beta-lactam
BCS class
Class III
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 4624
Dosage formHard-gelatin capsules
Oral

Acebutolol Hcl 400 mg

Route
Oral
Formulation type
Hard-capsule oral solid
Pharmacological class
Beta blocker
Manufacturing stream
Non-beta-lactam
BCS class
Class III
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 2727
Dosage formTablets
Oral

Amlodipine 2.5 mg, Bisoprolol Fumarate 5 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Beta blocker + Calcium-channel blocker
Manufacturing stream
Non-beta-lactam
BCS class
Class III (mixed)
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 4681
Dosage formHard-gelatin capsules
Oral

Amlodipine 2.5 mg, Metoprolol 25 mg

Route
Oral
Formulation type
Hard-capsule oral solid
Pharmacological class
Beta blocker + Calcium-channel blocker
Manufacturing stream
Non-beta-lactam
BCS class
Class III (mixed)
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 2733
Dosage formTablets
Oral

Amlodipine 2.5 mg, Metoprolol 25 mg (ER)

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Beta blocker + Calcium-channel blocker
Manufacturing stream
Non-beta-lactam
BCS class
Class III (mixed)
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 2734
Dosage formTablets
Oral

Amlodipine 25 mg, Metoprolol 25 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Beta blocker + Calcium-channel blocker
Manufacturing stream
Non-beta-lactam
BCS class
Class III (mixed)
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 2735
Dosage formTablets
Oral

Amlodipine 5 mg, Atenolol 25 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Beta blocker + Calcium-channel blocker
Manufacturing stream
Non-beta-lactam
BCS class
Class III
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 4683
Dosage formHard-gelatin capsules
Oral

Amlodipine 5 mg, Metoprolol 25 mg

Same composition also available as

Tablets

Route
Oral
Formulation type
Hard-capsule oral solid
Pharmacological class
Beta blocker + Calcium-channel blocker
Manufacturing stream
Non-beta-lactam
BCS class
Class III (mixed)
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 2756
Dosage formTablets
Oral

Amlodipine 5 mg, Metoprolol 25 mg

Same composition also available as

Hard-gelatin capsules

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Beta blocker + Calcium-channel blocker
Manufacturing stream
Non-beta-lactam
BCS class
Class III (mixed)
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 2757
Dosage formTablets
Oral

Amlodipine 5 mg, Metoprolol 25 mg (ER)

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Beta blocker + Calcium-channel blocker
Manufacturing stream
Non-beta-lactam
BCS class
Class III (mixed)
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 4686
Dosage formHard-gelatin capsules
Oral

Amlodipine Besylate 5 mg, Carvedilol Phosphate 10 mg (ER)

Route
Oral
Formulation type
Hard-capsule oral solid
Pharmacological class
Beta blocker + Calcium-channel blocker
Manufacturing stream
Non-beta-lactam
BCS class
Class II (mixed)
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 4687
Dosage formHard-gelatin capsules
Oral

Amlodipine Besylate 5 mg, Carvedilol Phosphate 20 mg (ER)

Route
Oral
Formulation type
Hard-capsule oral solid
Pharmacological class
Beta blocker + Calcium-channel blocker
Manufacturing stream
Non-beta-lactam
BCS class
Class II (mixed)
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 4711
Dosage formHard-gelatin capsules
Oral

Aspirin 100 mg, Atenolol 50 mg, Hydrochlorothiazide 12.5 mg, Ramipril 5 mg, Simvastatin 20 mg

Route
Oral
Formulation type
Hard-capsule oral solid
Pharmacological class
ACE inhibitor + Beta blocker + Salicylate analgesic / antiplatelet + Statin + Thiazide / thiazide-like diuretic
Manufacturing stream
Non-beta-lactam
BCS class
Class II (mixed)
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 4713
Dosage formHard-gelatin capsules
Oral

Aspirin 150 mg, Atorvastatin 10 mg, Metoprolol 25 mg, Ramipril 5 mg (ER)

Route
Oral
Formulation type
Hard-capsule oral solid
Pharmacological class
ACE inhibitor + Beta blocker + Salicylate analgesic / antiplatelet + Statin
Manufacturing stream
Non-beta-lactam
BCS class
Class II (mixed)
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 2825
Dosage formTablets
Oral

Aspirin 75 mg, Atenolol 25 mg, Lisinopril 5 mg, Simvastatin 10 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
ACE inhibitor + Beta blocker + Salicylate analgesic / antiplatelet + Statin
Manufacturing stream
Non-beta-lactam
BCS class
Class II (mixed)
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 2826
Dosage formTablets
Oral

Aspirin 75 mg, Atenolol 50 mg, Lisinopril 10 mg, Simvastatin 20 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
ACE inhibitor + Beta blocker + Salicylate analgesic / antiplatelet + Statin
Manufacturing stream
Non-beta-lactam
BCS class
Class II (mixed)
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 4719
Dosage formHard-gelatin capsules
Oral

Aspirin 75 mg, Atorvastatin 10 mg, Metoprolol 25 mg, Ramipril 5 mg (ER)

Route
Oral
Formulation type
Hard-capsule oral solid
Pharmacological class
ACE inhibitor + Beta blocker + Salicylate analgesic / antiplatelet + Statin
Manufacturing stream
Non-beta-lactam
BCS class
Class II (mixed)
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 2840
Dosage formTablets
Oral

Atenolol 100 mg, Chlorthalidone 25 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Beta blocker + Thiazide / thiazide-like diuretic
Manufacturing stream
Non-beta-lactam
BCS class
Class IV (mixed)
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 2841
Dosage formTablets
Oral

Atenolol 100 mg, Isosorbide Mononitrate 60 mg (SR)

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Beta blocker + Organic nitrate antianginal
Manufacturing stream
Non-beta-lactam
BCS class
Class III (mixed)
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 2842
Dosage formTablets
Oral

Atenolol 25 mg, Chlorthalidone 12.5 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Beta blocker + Thiazide / thiazide-like diuretic
Manufacturing stream
Non-beta-lactam
BCS class
Class IV (mixed)
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 2843
Dosage formTablets
Oral

Atenolol 25 mg, Chlorthalidone 6.25 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Beta blocker + Thiazide / thiazide-like diuretic
Manufacturing stream
Non-beta-lactam
BCS class
Class IV (mixed)
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 2844
Dosage formTablets
Oral

Atenolol 25 mg, Hydrochlorothiazide 12.5 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Beta blocker + Thiazide / thiazide-like diuretic
Manufacturing stream
Non-beta-lactam
BCS class
Class III
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 2845
Dosage formTablets
Oral

Atenolol 25 mg, Indapamide 1.5 mg (SR)

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Beta blocker + Thiazide / thiazide-like diuretic
Manufacturing stream
Non-beta-lactam
BCS class
Class II (mixed)
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Explore the product catalogue

Browse product pages by therapeutic area.

Browse compositions, strengths and dosage forms for third-party and contract manufacturing enquiries. Each product page includes its catalogue specification, manufacturing and packaging considerations, and a product-specific enquiry link. Confirm the applicable unit, documents and commercial terms with Walter.

How to read this catalogue

Permission is a starting point—not a supply commitment.

01

Therapeutic index

Primary areas provide buyer-friendly navigation. Combination products may reasonably sit across several clinical categories.

02

Facility confirmation

Current licence scope, site allocation, equipment fit and applicable segregation requirements are checked before commitment.

03

Product feasibility

Formula, strength, presentation, pack, target market, testing requirements and commercial scale are assessed together.

04

Responsible use

This B2B catalogue is not prescribing information, patient guidance or a representation that every composition is currently available for sale.

Start the conversation

Found a composition worth discussing?

Use the enquiry link on any record to carry its composition and dosage form into your manufacturing brief.

Request a quote
Quick chat on WhatsAppLet’s discuss your product